Pharmacovigilance Market

Pharmacovigilance Market (Drug Development: Preclinical Studies, Phase I, Phase II, Phase III, and Phase IV or Post Marketing Surveillance; Type of Method and Type of Service) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Pharmacovigilance Market Outlook 2028

  • The global market was valued at US$ 6.1 Bn in 2020
  • It is estimated to expand at a CAGR of 8.8% from 2021 to 2028
  • The global pharmacovigilance market is expected to reach the value of US$ 11.5 Bn by the end of 2028

Analysts’ Viewpoint on Pharmacovigilance (PV) Market Scenario

The global pharmacovigilance industry is growing cumulatively, as it is driven by increase in awareness within the public health sector coupled with rise in preference for safe medicines. This service is helping in surveillance of expected or unexpected effects that may appear or may be aggravated due to potential combination of drugs amid the ongoing COVID-19 pandemic. As such, the market for pharmacovigilance is anticipated to thrive at a significant CAGR during the years 2021 to 2028. Globally, the growing number of national pharmacovigilance centers is playing an imperative role to support the growth of the market over the next few years. Needless to mention, pharmacovigilance is witnessing numerous challenges to develop a better healthcare system. The unavailability of skilled labor and information about drugs obtained via the web could be two high-impact restraints of the market. However, rigorous pharmacovigilance activities that could be made compulsory are expected to fuel the demand for services in the market. Such mandatory activities help to actively manage high-risk medicines.

Advanced Clinical Trial Phases Fuelling Demand for Pharmacovigilance

Stakeholders in the pharmacovigilance market are extending their services in preclinical studies, and clinical trial phases I, II, III, and IV by phase of drug development. Phase IV a.k.a. post-marketing surveillance has contributed to a large share in terms of revenue in the previous years. Safety worries relating to marketed products, the growing necessity of designing systems to compare safety profiles of homologous medicinal products, and rising public health awareness campaigns are a few of the reasons contributing to the growth of the pharmacovigilance (PV) market.

Clinical trial phase III is predicted to set to rise at a high growth rate due to the escalating need for monitoring of drug safety. This phase emphasizes drug safety and efficiency in diverse sub-groups, where the benefit-risk ratio is developed, scrutinized, and updated accordingly. In order to be more accurate on the part of drug safety, biopharmaceutical companies are focusing on creating advanced clinical trial phases.

Pharmacovigilance Offers Health Transparency for COVID-19 Vaccines and Patient Monitoring

The need for pharmacovigilance services has increased due to the COVID-19 pandemic. Companies in the market for pharmacovigilance are taking advantage of this opportunity by increasing awareness about Coronavirus vaccine safety guidance. Information on each of the authorized vaccines, including authorization, manufacturing, and dosage, among other details, is fuelling the demand for pharmacovigilance services. This information is presented in layers, which allow sequential access to degrees of increasing depth of information. At the same time, pharmacovigilance monitoring of COVID-19 patients has become an international priority. Healthcare organizations are encouraging this activity in an attempt to guarantee health transparency.

Contract Outsourcing and Spontaneous Reporting Providing Impetus to Market Growth

The pharmacovigilance (PV) market is anticipated to grow at a promising rate due to the increasing demand for contract outsourcing and in-house pharmacovigilance. An important factor helping with the growth of contract outsourcing could be a shift in focus to core business activities from that non-core by outsourcing pharmacovigilance services. This will lead to a decrease in operational and financial costs suffered from delays in product approval.

The global pharmacovigilance market is positioned for a healthy growth rate throughout the assessment period. Intensified ADR (Adverse Drug Reaction) reporting, targeted spontaneous reporting, and cohort event monitoring activities are providing impetus to market growth. During recent years, in terms of revenue, the use of spontaneous reporting methods is growing at a rapid pace since it is a more accurate technique for discovering new ADRs.

North America and Asia Pacific Hold Lucrative Revenue Opportunities for Stakeholders

Asia Pacific is expected to gain high growth during the forecast period. Factors supporting market growth in this region are envisaged to include high demand for strict healthcare regulations and an increase in the number of clinical trials being set up. Nevertheless, developed regions are projected to significantly contribute to the pharmacovigilance market. For instance, North America’s cost-benefit gained by switching to contract research organization (CRO) outsourcing from expensive in-house activities are projected to help the region to collect a larger revenue share of the market.

Increased death rates due to adverse drug reactions and a rise in patient fears regarding the safety of medicinal products have propelled the North American market for pharmacovigilance in recent years. A report by the Centers for Disease Control and Prevention (CDC) states that there are around several thousand deaths caused by ADRs in the U.S., which are counted among the top 10 leading causes of death in the country.

Pharmacovigilance Industry: Overview

  • According to Transparency Market, Research’s latest report on the global pharmacovigilance market for the historical period 2017–2019 and forecast period 2021–2028, technological advancements, adoption of artificial intelligence, and automation are projected to drive the global pharmacovigilance (PV) market during the forecast period

Technological Advancements to Drive Global Pharmacovigilance Market

  • Automation and artificial intelligence in pharmacovigilance is a boom in the pharmaceutical industry. Amid the COVID-19 pandemic, technological advancements in pharmacovigilance have come to the rescue of the chaos of continuous clinical testing and delays in vaccine regulatory approval. The development of a centralized, web-based, and automated web portal for presenting the evaluation of the clinical trial studies related to the efficacy of the medicines used in managing COVID-19 diseases has enlightened physicians to improve the patient’s condition during the pandemic.
  • The usage of machine learning and advanced data analytics has created a paradigm shift in the development of drugs, assessment of drug risk profiles, overview of patients' safety, and optimal patient treatment
  • Automation, artificial intelligence, and analytics have driven the efficiency of companies in providing pharmacovigilance services. Technically advanced automation, machine learning, and artificial intelligence are likely to create a paradigm shift in pharmacovigilance in the near future

A rise in Cases of Adverse Drug Reactions and Drug Toxicity

  • A surge in the incidence of adverse drug reactions globally due to the high rate of drug consumption among the population is expected to propel the global pharmacovigilance market
  • The lack of well-documented post-marketing adverse drug reaction reporting is projected to restrain the global market for pharmacovigilance. Hence, under-reporting of adverse drug reactions would result in an increase in drug toxicity incidences, which, in turn, is likely to augment the global pharmacovigilance business.
  • The increase in adverse drug reactions has compelled the regulatory authorities to adopt more stringent steps pertaining to pharmacovigilance. In August 2020, according to research studies, the average occurrence of incidence of adverse drug reactions among hospitalized pediatric patients was reported to be 9.52%.

High Risk Associated with Data Security in Pharmacovigilance Outsourcing to Hamper Market

  • Organizations are becoming increasingly connected through new platforms such as the cloud and social media. Hence, there has been a consequent rise in potential threats to data security, the complexity of attacks, and the intensity of breaches. It is imperative for the healthcare industry to protect proprietary and confidential information related to services and products, as there is a high risk of their confidentiality being compromised.
  • Healthcare and pharmaceutical companies prefer to partner with CROs that can provide and support a high level of data security services. The contract research organization needs to assure the pharmaceutical companies that their platforms are secure, in adherence to the prescribed industry standards, and in compliance with the regulatory guidelines on data protection.
  • Despite the growing pharmacovigilance outsourcing process, pharmaceutical companies still find considering service providers reliable a major challenge, as several instances of data security breaches have been reported in the past, including illegal access to personal data through the Internet

Pharmacovigilance Market: Competition Landscape

  • This report profiles major players in the global pharmacovigilance market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global market is highly established with the presence of a number of international as well as regional players
  • Leading players operating in the global pharmacovigilance business are
    • Accenture plc
    • Bristol-Myers Squibb
    • Clinquest Group B.V.
    • Cognizant
    • Labcorp Drug Development
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • ICON plc
    • iGATE Corporation
    • iMEDGlobal Corporation
    • Syneos Health
    • Novartis AG
    • PAREXEL International Corporation
    • Pfizer, Inc.
    • Pharmaceutical Product Development, LLC. (PPD)
    • IQVIA
    • Sanofi
    • Synowledge LLC
    • Wipro Limited

Pharmacovigilance Market: Key Developments

  • Key players in the global pharmacovigilance market are engaged in technological advancements such as Big Data analytics, cloud-based database, and automation. These strategies are likely to fuel the growth of the global market for pharmacovigilance. A few expansion strategies adopted by players operating in the global market are:
    • In May 2021, Cognizant reported that its pharmacovigilance services were rated best in the industry. The company offers advanced pharmacovigilance services, which ensure the safety of the patients and lowers drug adverse events.
    • In 2020, the U.K. Government entered into a deal with Genpact, a U.S.-based company, for EUR 1.5 Mn to develop an artificial intelligence tool for screening adverse drug reaction (ADR) reports for vaccine
    • In October 2021, Syneos Health acquired RxDataScience, a data analytics and artificial intelligence company. This will strengthen the company's large data sets for decentralized trials and the patient journey.
  • The report on the global pharmacovigilance market discussed individual strategies, followed by company profiles of pharmacovigilance services. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global pharmacovigilance industry.

Pharmacovigilance (PV) Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 6.1 Bn

Market Forecast Value in 2028

US$ 11.5 Bn

Growth Rate (CAGR)

8.8% (Year-on-Year)

Forecast Period

2021–2028

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross-segment and regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Drug Development
    • Preclinical Studies
    • Phase I
    • Phase II
    • Phase III
    • Phase IV or Post Marketing Surveillance
  • Type of Methods
    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining
  • Type of Service
    • In-house
    • Contract Outsourcing

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & NewZealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Accenture plc
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant
  • Labcorp Drug Development
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ICON plc
  • iGATE Corporation
  • iMEDGlobal Corporation
  • Syneos Health
  • Novartis AG
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • Pharmaceutical Phase of Drug Development, LLC. (PPD)
  • IQVIA
  • Sanofi
  • Synowledge LLC
  • Wipro Limited

Customization Scope

Available upon request

Pricing

Available upon request

Pharmacovigilance Market – Segmentation

Drug Development
  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance
Type of Methods
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
Type of Service
  • In-house
  • Contract Outsourcing
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of pharmacovigilance market?

The global market for pharmacovigilance was worth US$ 6.1 Bn and is projected to reach a value of US$ 11.5 Bn by the end of 2028

What is the anticipated CAGR of the pharmacovigilance (PV) market in the forecast period?

The pharmacovigilance market is anticipated to grow at a CAGR of 8.8% during the forecast period

Which region is expected to project the highest market share in the global market for pharmacovigilance?

North America accounted for a major share of the global pharmacovigilance market

What are the key driving factors for the growth of the pharmacovigilance industry?

The pharmacovigilance (PV) market is growing cumulatively, as it is driven by an increase in awareness within the public health sector coupled with rise in preference for safe medicines

Who are the key players in the global pharmacovigilance business?

Key players in the global pharmacovigilance industry include Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, ICON plc, iGATE Corporation, iMEDGlobal Corporation, Syneos Health, Novartis AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), IQVIA, Sanofi, Synowledge LLC, and Wipro Limited

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Pharmacovigilance Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017–2028

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. COVID-19 Impact on the Pharmacovigilance Market

        5.2. Technological Advancements (big data analytics, cloud-based database, automation)

        5.3. Drugs Regulatory Framework of Pharmacovigilance Market

        5.4. Pharmacovigilance Market: Value Chain Analysis

        5.5. Pharmacovigilance Market: Porter’s Five Forces Analysis

        5.6. Overview of Drugs Adverse Effects

    6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017–2028

            6.2.1. Preclinical Studies

            6.2.2. Phase I

            6.2.3. Phase II

            6.2.4. Phase III

            6.2.5. Phase IV or Post Marketing Surveillance

        6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method

        7.1. Introduction & Definition

            7.1.1. Key Findings / Developments

        7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017–2027

            7.2.1. Spontaneous Reporting

            7.2.2. Intensified ADR Reporting

            7.2.3. Targeted Spontaneous Reporting

            7.2.4. Cohort Event Monitoring

            7.2.5. EHR Mining

        7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028

    8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service

        8.1. Introduction & Definition

            8.1.1. Key Findings / Developments

        8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017–2027

            8.2.1. In-house

            8.2.2. Contract Outsourcing

        8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    9. Global Pharmacovigilance Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Pharmacovigilance Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

    10. North America Pharmacovigilance Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

            10.2.1. Preclinical Studies

            10.2.2. Phase I

            10.2.3. Phase II

            10.2.4. Phase III

            10.2.5. Phase IV or Post Marketing Surveillance

        10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

            10.3.1. Spontaneous Reporting

            10.3.2. Intensified ADR Reporting

            10.3.3. Targeted Spontaneous Reporting

            10.3.4. Cohort Event Monitoring

            10.3.5. EHR Mining Others

        10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

            10.4.1. In-house

            10.4.2. Contract Outsourcing

        10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028

            10.6.1. By Phase of Drug Development

            10.6.2. By Type of Method

            10.6.3. By Type of Service

            10.6.4. By Country

    11. Europe Pharmacovigilance Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

            11.2.1. Preclinical Studies

            11.2.2. Phase I

            11.2.3. Phase II

            11.2.4. Phase III

            11.2.5. Phase IV or Post Marketing Surveillance

        11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

            11.3.1. Spontaneous Reporting

            11.3.2. Intensified ADR Reporting

            11.3.3. Targeted Spontaneous Reporting

            11.3.4. Cohort Event Monitoring

            11.3.5. EHR Mining

        11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

            11.4.1. In-house

            11.4.2. Contract Outsourcing

        11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028

            11.6.1. By Phase of Drug Development

            11.6.2. By Type of Method

            11.6.3. By Type of Service

            11.6.4. By Country/Sub-region

    12. Asia Pacific Pharmacovigilance Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

            12.2.1. Preclinical Studies

            12.2.2. Phase I

            12.2.3. Phase II

            12.2.4. Phase III

            12.2.5. Phase IV or Post Marketing Surveillance

        12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

            12.3.1. Spontaneous Reporting

            12.3.2. Intensified ADR Reporting

            12.3.3. Targeted Spontaneous Reporting

            12.3.4. Cohort Event Monitoring

            12.3.5. EHR Mining

        12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

            12.4.1. In-house

            12.4.2. Contract Outsourcing

        12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028

            12.6.1. By Phase of Drug Development

            12.6.2. By Type of Method

            12.6.3. By Type of Service

            12.6.4. By Country/Sub-region

    13. Latin America Pharmacovigilance Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

            13.2.1. Preclinical Studies

            13.2.2. Phase I

            13.2.3. Phase II

            13.2.4. Phase III

            13.2.5. Phase IV or Post Marketing Surveillance

        13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

            13.3.1. Spontaneous Reporting

            13.3.2. Intensified ADR Reporting

            13.3.3. Targeted Spontaneous Reporting

            13.3.4. Cohort Event Monitoring

            13.3.5. EHR Mining

        13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

            13.4.1. In-house

            13.4.2. Contract Outsourcing

        13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028

            13.6.1. By Phase of Drug Development

            13.6.2. By Type of Method

            13.6.3. By Type of Service

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027

            14.2.1. Preclinical Studies

            14.2.2. Phase I

            14.2.3. Phase II

            14.2.4. Phase III

            14.2.5. Phase IV or Post Marketing Surveillance

        14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027

            14.3.1. Spontaneous Reporting

            14.3.2. Intensified ADR Reporting

            14.3.3. Targeted Spontaneous Reporting

            14.3.4. Cohort Event Monitoring

            14.3.5. EHR Mining

        14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027

            14.4.1. In-house

            14.4.2. Contract Outsourcing

        14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028

            14.6.1. By Phase of Drug Development

            14.6.2. By Type of Method

            14.6.3. By Type of Service

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share / Position Analysis, by Company, 2020

        15.3. Competitive Business Strategies

        15.4. Company Profiles

            15.4.1. Accenture plc

                15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.1.2. Phase of Drug Development Portfolio

                15.4.1.3. Financial Overview

                15.4.1.4. Strategic Overview

                15.4.1.5. SWOT Analysis

            15.4.2. Bristol-Myers Squibb

                15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.2.2. Phase of Drug Development Portfolio

                15.4.2.3. Financial Overview

                15.4.2.4. Strategic Overview

                15.4.2.5. SWOT Analysis

            15.4.3. Clinquest Group B.V.

                15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.3.2. Phase of Drug Development Portfolio

                15.4.3.3. Financial Overview

                15.4.3.4. Strategic Overview

                15.4.3.5. SWOT Analysis

            15.4.4. Cognizant

                15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.4.2. Phase of Drug Development Portfolio

                15.4.4.3. Financial Overview

                15.4.4.4. Strategic Overview

                15.4.4.5. SWOT Analysis

            15.4.5. Labcorp Drug Development

                15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.5.2. Phase of Drug Development Portfolio

                15.4.5.3. Financial Overview

                15.4.5.4. Strategic Overview

                15.4.5.5. SWOT Analysis

            15.4.6. F. Hoffmann-La Roche Ltd.

                15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.6.2. Phase of Drug Development Portfolio

                15.4.6.3. Financial Overview

                15.4.6.4. Strategic Overview

                15.4.6.5. SWOT Analysis

            15.4.7. GlaxoSmithKline plc

                15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.7.2. Phase of Drug Development Portfolio

                15.4.7.3. Financial Overview

                15.4.7.4. Strategic Overview

                15.4.7.5. SWOT Analysis

            15.4.8. ICON plc

                15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.8.2. Phase of Drug Development Portfolio

                15.4.8.3. Financial Overview

                15.4.8.4. Strategic Overview

                15.4.8.5. SWOT Analysis

            15.4.9. iGATE Corporation

                15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.9.2. Phase of Drug Development Portfolio

                15.4.9.3. Financial Overview

                15.4.9.4. Strategic Overview

                15.4.9.5. SWOT Analysis

            15.4.10. iMEDGlobal Corporation

                15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.10.2. Phase of Drug Development Portfolio

                15.4.10.3. Strategic Overview

                15.4.10.4. SWOT Analysis

            15.4.11. Syneos Health

                15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.11.2. Phase of Drug Development Portfolio

                15.4.11.3. Financial Overview

                15.4.11.4. Strategic Overview

                15.4.11.5. SWOT Analysis

            15.4.12. Novartis AG

                15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.12.2. Phase of Drug Development Portfolio

                15.4.12.3. Financial Overview

                15.4.12.4. Strategic Overview

                15.4.12.5. SWOT Analysis

            15.4.13. PAREXEL International Corporation

                15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.13.2. Phase of Drug Development Portfolio

                15.4.13.3. Financial Overview

                15.4.13.4. Strategic Overview

                15.4.13.5. SWOT Analysis

            15.4.14. Pfizer, Inc.

                15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.14.2. Phase of Drug Development Portfolio

                15.4.14.3. Financial Overview

                15.4.14.4. Strategic Overview

                15.4.14.5. SWOT Analysis

            15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)

                15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.15.2. Phase of Drug Development Portfolio

                15.4.15.3. Financial Overview

                15.4.15.4. Strategic Overview

                15.4.15.5. SWOT Analysis

            15.4.16. IQVIA

                15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.16.2. Phase of Drug Development Portfolio

                15.4.16.3. Financial Overview

                15.4.16.4. Strategic Overview

                15.4.16.5. SWOT Analysis

            15.4.17. Sanofi

                15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.17.2. Phase of Drug Development Portfolio

                15.4.17.3. Financial Overview

                15.4.17.4. Strategic Overview

                15.4.17.5. SWOT Analysis

            15.4.18. Synowledge LLC

                15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.18.2. Phase of Drug Development Portfolio

                15.4.18.3. Strategic Overview

                15.4.18.4. SWOT Analysis

            15.4.19. Wipro Limited

                15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.19.2. Phase of Drug Development Portfolio

                15.4.19.3. Financial Overview

                15.4.19.4. Strategic Overview

                15.4.19.5. SWOT Analysis

    List of Tables

    Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017–2028

    Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017–2028

    Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028

    Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028

    Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028

    Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    List of Figures

    Figure 01: Pharmacovigilance Market Snapshot

    Figure 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

    Figure 03: Market Value Share, by Phase of Drug Development, 2018

    Figure 04: Market Value Share, by Type of Service, 2018

    Figure 05: Market Value Share, by Region, 2018

    Figure 06: Global Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Preclinical Studies, 2017–2028

    Figure 08: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase I, 2017–2028

    Figure 09: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase II, 2017–2028

    Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase III, 2017–2028

    Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase IV or Post Marketing Surveillance, 2017–2028

    Figure 12: Global Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Phase of Drug Development

    Figure 13: Global Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), Spontaneous Reporting, 2017–2028

    Figure 15: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intensified ADR Reporting, 2017–2028

    Figure 16: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Spontaneous Reporting, 2017–2028

    Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cohort Event Monitoring, 2017–2028

    Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EHR Mining, 2017–2028

    Figure 19: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2028

    Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 21: Global Pharmacovigilance Market Value Share Analysis, by Type of Service Providers, 2020 and 2028

    Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2017–2028

    Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsourcing, 2017–2028

    Figure 24: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 25: Global Pharmacovigilance Market Value Share Analysis, by Region, 2020 and 2028

    Figure 26: Global Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

    Figure 27: North America Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

    Figure 28: North America Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028

    Figure 29: North America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 30: North America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 31: North America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

    Figure 32: North America Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028

    Figure 33: North America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    Figure 34: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 35: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 36: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

    Figure 37: Europe Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028

    Figure 38: Europe Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 39: Europe Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 40: Europe Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

    Figure 41: Europe Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028

    Figure 42: Europe Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    Figure 43: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 44: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 45: Asia Pacific Pharmacovigilance Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017– 2028

    Figure 46: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Country 2021–2028

    Figure 47: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 48: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 49: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

    Figure 50: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Country, 2018 and 2027

    Figure 51: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    Figure 52: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 53: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 54: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 55: Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Country/Sub-region, 2021–2028

    Figure 56: Latin America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 57: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 58: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

    Figure 59: Latin America Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 60: Latin America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    Figure 61: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 62: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 63: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028

    Figure 64: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 65: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028

    Figure 66: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028

    Figure 67: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028

    Figure 68: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 69: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

    Figure 70: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028

    Figure 71: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

    Figure 72: Global Pharmacovigilance Market Share Analysis, by Company (2020)

Copyright © Transparency Market Research, Inc. All Rights reserved